Rocket Pharmaceuticals Inc
NASDAQ:RCKT 2:44:43 PM EDT
Products, Regulatory
Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker And Preliminary Functional Data From Phase 1 Trial Of Rp-A501
Published: 12/08/2020 21:36 GMT
Rocket Pharmaceuticals Inc (RCKT) - Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data From Phase 1 Trial of Rp-a501 for the Treatment of Danon Disease.
Rocket Pharmaceuticals Inc - Rp-a501 Showed a Manageable Safety Profile in Three Patients Treated in Low Dose Cohort.
Rocket Pharmaceuticals Inc - No Unexpected Drug Product Related Adverse Events Or Severe Adverse Events Were Observed in Trial.
Rocket Pharmaceuticals - Decreases in Cardiac Biomarker Bnp of >50% and Stabilization of Clinical Biomarkers Ck-mb and Transaminases in Two Patients.
Rocket Pharmaceuticals - Safety Assessment in 2 Adult Patients Treated in Higher Dose Cohort Ongoing.
Rocket Pharmaceuticals -in Higher Dose Cohort, 1 Drug Product Related Serious Adverse Event, Resolved Following Intensified Immunosuppressive Therapy.
Rocket Pharmaceuticals Inc - Rp-a501 Showed a Manageable Safety Profile in Three Patients Treated in Low Dose Cohort.
Rocket Pharmaceuticals Inc - No Unexpected Drug Product Related Adverse Events Or Severe Adverse Events Were Observed in Trial.
Rocket Pharmaceuticals - Decreases in Cardiac Biomarker Bnp of >50% and Stabilization of Clinical Biomarkers Ck-mb and Transaminases in Two Patients.
Rocket Pharmaceuticals - Safety Assessment in 2 Adult Patients Treated in Higher Dose Cohort Ongoing.
Rocket Pharmaceuticals -in Higher Dose Cohort, 1 Drug Product Related Serious Adverse Event, Resolved Following Intensified Immunosuppressive Therapy.